RegCell raised $66 million to advance its regulatory T-cell (Treg) immune tolerance platform toward the clinic. The round combines a fully subscribed $44 million Series A financing with a $22 million non-dilutive grant from Japan’s AMED. The company, associated with Nobel laureate Shimon Sakaguchi’s long-running Treg research, framed the funding as a step toward translating its immune tolerance technology into clinical development programs. Non-dilutive support from AMED also signals continued government backing for cell-based immunomodulation. For the broader CGT/immune tolerance field, the financing highlights sustained investor appetite for next-generation Treg platforms, particularly those with differentiated translational strategy and strong preclinical positioning.